Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Sample size determination in Bayesian randomized phase II trial design often relies on computationally intensive search methods, presenting challenges in terms of feasibility and efficiency. We propose a novel approach that greatly reduces the computing time of sample size calculations for Bayesian trial designs. Our approach innovatively connects group sequential design with Bayesian trial design and leverages the proportional relationship between sample size and the squared drift parameter. This results in a faster algorithm. By employing regression analysis, our method can accurately pinpoint the required sample size with significantly reduced computational burden. Through theoretical justification and extensive numerical evaluations, we validate our approach and illustrate its efficiency across a wide range of common trial scenarios, including binary endpoint with Beta-Binomial model, normal endpoint, binary/ordinal endpoint under Bayesian generalized linear model, and survival endpoints under Bayesian piecewise exponential models. To facilitate the use of our methods, we create an R package named "BayesSize" on GitHub.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pst.70037DOI Listing

Publication Analysis

Top Keywords

sample size
20
drift parameter
8
size determination
8
bayesian randomized
8
trial design
8
bayesian trial
8
bayesian
6
sample
5
size
5
parameter based
4

Similar Publications

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Neurology

October 2025

Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.

Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).

View Article and Find Full Text PDF

Negative symptoms, depression, and cognitive impairments of the schizophrenia spectrum have been associated with difficulties in daily functioning. Compensatory Cognitive Training (CCT) has shown positive effects on cognition, negative symptoms, and functioning in this population. The main objective of this pilot study was to analyze the effects of CCT on cognition and functioning in a group schizophrenia spectrum outpatients in Mexico.

View Article and Find Full Text PDF

Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.

View Article and Find Full Text PDF

Objectives Background: Monocyte anisocytosis (monocyte distribution width [MDW]) has been previously validated to predict sepsis and outcome in patients presenting in the emergency department and mixed-population ICUs. Determining sepsis in a critically ill surgical/trauma population is often difficult due to concomitant inflammation and stress. We examined whether MDW could identify sepsis among patients admitted to a surgical/trauma ICU and predict clinical outcome.

View Article and Find Full Text PDF

This study introduces the Wrapped Epanechnikov Exponential Distribution (WEED), a novel circular distribution derived from the Epanechnikov exponential distribution. The probability density function and cumulative distribution function are presented, together with a comprehensive analysis of its properties and parameters, including the characteristic function and trigonometric moments. Parameters are estimated using maximum likelihood estimation (MLE).

View Article and Find Full Text PDF